Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read More
Tag: Ozempic
Novo Nordisk files for EU approval of Ozempic in type II diabetes
Patients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss.
Read More
Novo Nordisk testing behavioural science to improve patient support
Novo Nordisk presents ‘Ozempic’ interface at eyeforpharma conference in Barcelona.
Read More
Ozempic launched for type II diabetes in the UK
Novo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK.
Read More
Novo’s Ozempic beats Lilly’s Trulicity on weight loss
Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in adults with type II diabetes.
Read More
Novo’s oral semaglutide beats Lilly/Boehringer’s Jardiance
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read More
EU approves Novo’s once-weekly diabetes therapy
European regulators have issued a green light for Novo Nordisk’s once-weekly diabetes therapy Ozempic.
Read More
Novo bags first approval for once-weekly diabetes drug
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
